Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR4 | P51679 | 5/20 | 0.44 |
| ▸ | MELK | Q14680 | 3/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.40 |
| ▸ | FLT3 | P36888 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 4/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.37 |
| ▸ | CCR2 | P41597 | 2/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17829832 | 0.84 | MELK (0.49) | CCR4MELKKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17829842 | 0.84 | CCR4 (0.51) | CCR4MELKKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17829840 | 0.84 | CCR4 (0.54) | CCR4MELKFLT3CACNA2D1 | |
| SCHEMBL17829846 | 0.83 | CCR4 (0.50) | CCR4MELKKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17829801 | 0.83 | CCR4 (0.53) | CCR4MELKKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17829860 | 0.81 | KCNH2 (0.47) | KDM4EALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL17829827 | 0.81 | CCR4 (0.49) | CCR4MELKKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17833285 | 0.79 | MAPT (0.42) | KDM4EALDH1A1CYP3A4TSHRHSD17B10 | |
| SCHEMBL17829833 | 0.77 | CCR4 (0.49) | CCR4MELKKDM4EALDH1A1CYP3A4 | |
| SCHEMBL17829823 | 0.77 | CCR4 (0.49) | CCR4MELKKDM4EALDH1A1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS (US) | 2016-06-16 | — | — | US | disclosed |
| WO-2016094730-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | SYNERECA PHARMACEUTICALS, INC. (US) | 2016-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168140-A1 | HETEROCYCLIC COMPOUNDS AS ANTIBIOTIC POTENTIATORS | FOS, FOSB, YAP1 | CCR4 4472/4885MELK 1849/4885KDM4E 4525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.